Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis

被引：71

作者：

Itakura, J ^{[1
]}

Izumi, N ^{[1
]}

Nishimura, Y ^{[1
]}

Inoue, K ^{[1
]}

Ueda, K ^{[1
]}

Nakanishi, H ^{[1
]}

Tsuchiya, K ^{[1
]}

Hamano, K ^{[1
]}

Asahina, Y ^{[1
]}

Kurosaki, M ^{[1
]}

Uchihara, M ^{[1
]}

Miyake, S ^{[1
]}

机构：

[1] Musashino Red Cross Hosp, Div Gastroenterol & Hepatol, Musashino, Tokyo 1808610, Japan

来源：

HEPATOLOGY RESEARCH | 2004年 / 29卷 / 04期

关键词：

primary biliary cirrhosis; UDCA; bezafibrate; randomized crossover trial;

D O I：

10.1016/j.hepres.2004.04.001

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The aim of this study was to evaluate the effects of the combination therapy with bezafibrate and ursodeoxycholic acid (UDCA) for primary biliary cirrhosis (PBC), compared to UDCA monotherapy. Sixteen patients with compensated PBC were divided randomly into two groups. Group A received treatment with bezafibrate and UDCA for 6 months, while group B received UDCA alone, treatment protocols were then exchanged for another 6 months. The laboratory data was followed every month. The mean levels of alkaline phosphatase (ALP) decreased significantly more in group A than in group B in the first half of the study. Then serum ALP levels were elevated in group A after exchanged the therapy, but fell down in group B. Serum levels of gamma-glutamyl transferase (GGT), immunoglobulin M and triglycerides values were significantly lower in group B than in group A, after changing therapies from monotherapy to combination therapy with bezafibrate and UDCA. The mean levels of ALP, GGT and triglycerides were significantly lower at the end of the combination therapy than those at the end of the monotherapy. The combination therapy with bezatibrate and UDCA significantly improves the laboratory data that specific for PBC in comparison with UDCA monotherapy. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：216 / 222

页数：7

共 25 条

[11] Bezafibrate treatment: a new medical approach for PBC patients? [J].

Kanda, T ;

Yokosuka, O ;

Imazeki, F ;

Saisho, H .

JOURNAL OF GASTROENTEROLOGY, 2003, 38 (06) :573-578

[12] Use of ursodeoxycholic acid in liver diseases [J].

Kumar, D ;

Tandon, RK .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (01) :3-14

[13] Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis [J].

Leuschner, M ;

Guldutuna, S ;

You, TG ;

Hubner, K ;

Bhatti, S ;

Leuschner, U .

JOURNAL OF HEPATOLOGY, 1996, 25 (01) :49-57

[14] URSODEOXYCHOLIC ACID IN PRIMARY BILIARY-CIRRHOSIS - RESULTS OF A CONTROLLED DOUBLE-BLIND TRIAL [J].

LEUSCHNER, U ;

FISCHER, H ;

KURTZ, W ;

GULDUTUNA, S ;

HUBNER, K ;

HELLSTERN, A ;

GATZEN, M ;

LEUSCHNER, M .

GASTROENTEROLOGY, 1989, 97 (05) :1268-1274

[15] URSODEOXYCHOLIC ACID IN THE TREATMENT OF PRIMARY BILIARY-CIRRHOSIS [J].

LINDOR, KD ;

DICKSON, ER ;

BALDUS, WP ;

JORGENSEN, RA ;

LUDWIG, J ;

MURTAUGH, PA ;

HARRISON, JM ;

WIESNER, RH ;

ANDERSON, ML ;

LANGE, SM ;

LESAGE, G ;

ROSSI, SS ;

HOFMANN, AF .

GASTROENTEROLOGY, 1994, 106 (05) :1284-1290

[16] NEW CONCEPTS IN BILIARY-CIRRHOSIS [J].

LUDWIG, J .

SEMINARS IN LIVER DISEASE, 1987, 7 (04) :293-301

[17]

Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P1518

[18] Primary biliary cirrhosis [J].

Neuberger, J .

LANCET, 1997, 350 (9081) :875-879

[19] An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis [J].

Neuman, MG ;

Cameron, RG ;

Haber, JA ;

Katz, GG ;

Blendis, LM .

LIVER, 2002, 22 (03) :235-244

[20]

Papatheodoridis GV, 2002, AM J GASTROENTEROL, V97, P2063

← 1 2 3 →